Healthy profit growth at Richter Gedeon

12 August 2001

Richter Gedeon of Hungary has reported a 37.3% climb in net profits to12.04 billion forint ($42.6 million) for the six months ended June 30, while sales increased 30.3% to 44.71 billion forint. Domestic turnover rose 28.4% to 12.29 billion forint, and the company noted that exports reached $111.1 million, a rise of 20.9%.

Richter said that the rise in domestic revenues is partly the result of stockpiling by wholesalers and pharmacies ahead of 6.3% price increases as of July 1. The company added that the recently-signed pricing agreement with the Hungarian government "has also made possible that new products should come to the market in the coming months." These are expected to include antidepressants, anti-inflammatory fungicide products and hormone supplements.

In the Commonwealth of Independent States, Richter's sales amounted to $43.4 million, a 29.9% rise driven by a 52% increase in revenues from oral contraceptives. In Russia alone, sales amounted to $32.4 million, according to a Reuters report.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight